Apogee Therapeutics (APGE) reported a Q1 net loss Monday of $55.3 million, widening from a loss of $32.1 million a year earlier.
Analysts polled by FactSet expected a loss of $72.3 million.
The company reported no revenue for the quarter ended March 31, as expected by analysts.
Apogee reported cash, cash equivalents and marketable securities of $681.4 million as of March 31. These should be enough to allow the company to fund its operating expenses into Q1 2028, it said.
Apogee shares were up 5.6% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。